Table 2

Cytokine responses to murine CII in mice treated with A12-immune T cells




Antibodies to CII




VB8+, VB14+ T cells

283 ± 25

(P ≤ 0.05)

2,826 ± 320

(P ≤ 0.03)

29 ± 5

(P < 0.05)

29 ± 3

(P ≤ 0.05)

VB8-, VB14- T cells

2,570 ± 120

10,856 ± 75

10 ± 2

77 ± 30

Inguinal lymph node cells from A12-immunized DR1 mice were fractionated into a Vβ8, Vβ14+ population and a Vβ8, Vβ14- population by using ferromagnetic beads. DR1 mice (n = 10 for each group) were immunized with CII/CFA, and on day 23 after immunization, when arthritis was established, each mouse was infused intravenously with 5 × 105 cells of either Vβ8, Vβ14+ T cells or Vβ8, Vβ14- T cells. To confirm the importance of the cytokine responses after cell transfer in vivo, inguinal lymph node cells were taken from the mice 28 days after treatment and were cultured with murine collagen so that supernatants could be analyzed for the presence of cytokines. When cultures from mice treated with the Vβ8+, Vβ14+ cells were compared with those from mice treated with the Vβ8-, Vβ14- cells, the IL-4 response to murine collagen was elevated, whereas the inflammatory cytokines (IFN-γ and IL-17), were suppressed. Mean antibody titers to CII in sera taken 6 weeks after immunization were similarly suppressed in mice given the Vβ8, Vβ14+, enriched T cells, compared with mice given Vβ8, Vβ14- CD4+ T cells.

Kimata et al. Arthritis Research & Therapy 2012 14:R107   doi:10.1186/ar3832

Open Data